In addition, overexpression of FOXM1 reduces the sensitivity of HER2-positive breast cancer cells to lapatinib, while inhibition of FOXM1 rescues resistance to lapatinib resistance [33], [34]. This evidence concerns the gene ERBB2 and breast cancer.